Archive for the ‘Cascade Technologies Inc. CSDT’ Category

Cascade Technologies Corp. (CSDT.OB) Subsidiary Appoints Seasoned VP for International Business Development

Tuesday, October 5th, 2010

Spectral Molecular Imaging, a wholly owned subsidiary of Cascade Technologies Corp., today announced the appointment of Dr. Sam Raz as the company’s vice president for International Business Development.

Spectral Molecular is a development-stage medical imaging device company. The company uses its proprietary hyperspectral-optical imaging technology to advance the early and accurate diagnoses of cancer and precancerous conditions.

Dr. Daniel L. Farkas, chairman and CEO of Spectral Molecular, said the Dr. Raz’s experience and skill sets complement the company’s focus.

“Sam is an old friend and an exceptionally experienced and capable individual, who can greatly contribute to our company’s efforts,” Dr. Farkas stated in the press release. “The ambitious agenda that we have defined and are pursuing can only be made successful by bringing together the right talents, in a strategic way, and Dr. Raz is a pivotal new addition to our team in this regard. He will be managing our international connections, in research, clinical development and business alike, focusing geographically on Europe and Israel in his first year, since he is bringing to the task an unmatched set of existing relationships and expertise.”

Dr. Raz has a Bachelor of Science in environmental public health and bacteriology from UCLA, where he was awarded the American Hospital Association-Kellogg Foundation Award; the National Center for Health Services Research Award; the University of Pennsylvania National Health Care Management Center Award; the Los Angeles County Health and Hospital Department Distinction Award; the University of Michigan School of Public Health Crosby Award; and three UCLA scholarship awards.

In 2004, Dr. Raz served as president of Mind Fountain – Medical Technology Inc. He has also served as CEO of three start-ups: the Dynamic Memory External Fixator developed at Hadassah Medical Center, Jerusalem; the Female Incontinence Device developed at the most prestigious RAD Biomed Life Science Incubator; and the Skin Melanoma Detection and Cosmetic Assessment System developed at The Hebrew University of Jerusalem.

Dr. Raz also formed Advanced Dental Technologies in the UK and Germany to commercialize five dental products focusing on high quality dental implants and restorative accessories.

Previous endeavors also include the founding and position of CEO for The Variety Center, an Israeli national center for the advancement and diagnosis of children’s disabilities, where he developed 12 types of innovative intervention programs for handicapped children.

For the past six years, Dr. Raz served as CEO of Shiluv, a non-profit organization for the integration of Down Syndrome and normative preschool children. In addition, he was recently appointed the chairman of EMILI, a pre-school not-for-profit organization.

For more information please visit www.spectralmi.com

Let us hear your thoughts below:

Cascade Technologies Corp. (CSDT.OB) is “One to Watch”

Wednesday, May 26th, 2010

Spectral Molecular Imaging, Inc., a medical imaging device company recently acquired by Cascade Technologies, is focused on developing non-invasive devices that use patented technology for improved clinical diagnostics, primarily in the field of cancer pathology. These devices utilize high-resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via spectral-imaging approaches. The company also plans to provide services related to its primary products, including software modules and maintenance services.

The company’s optical diagnostic products are being designed for operation in conjunction with surgical and/or evaluation procedures in real time. Spectral Molecular’s technology is anticipated to enable early detection and more reliable diagnosis of various diseases, such as Barrett’s esophagus, lung cancer, and melanoma. The end result will be significant improvement in long-term patient outcomes and substantial reduction in overall costs for the healthcare system.

Spectral Molecular was established by Daniel L. Farkas, Ph.D. and a group of others. While working at Carnegie Mellon University directing the Center for Light Microscope Imaging and Biotechnology, a national science and technology center, Dr. Farkas and his colleagues conducted development work and intellectual property protection on acousto-optic tunable filters for high-resolution, hyperspectral optical bioimaging. Spectral Molecular was formed to further develop and commercialize this approach and other optical molecular imaging technologies to save lives and improve patient outcomes.

Targeting multiple applications, end-user markets, and potential revenue streams, Spectral Molecular intends to develop three products: the MelaSpect™ device, the EndoSpect™ device, and the OxySpect™ device. These devices are being developed to address the early detection of skin cancer, to more accurately investigate tissue status during gastrointestinal and pulmonary endoscopy, and for mapping tissue oxygenation during and after surgical intervention, respectively.

Let us hear your thoughts: Cascade Technologies, Inc. Message Board